NCT03762031View on ClinicalTrials.gov

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

March 4, 2020

Study Completion Date

March 4, 2020

Conditions
Healthy
Interventions
DRUG

GC4711 30mg

single dose given via a 15 minute intravenous infusion

DRUG

GC4711 60mg

single dose given via a 15 minute intravenous infusion

DRUG

GC4711 90mg

single dose given via a 15 minute intravenous infusion

DRUG

GC4711 120mg

single dose given via a 15 minute intravenous infusion

DRUG

Placebo

single dose of normal saline given via a 15 minute intravenous infusion

DRUG

GC4711 75mg

single dose given via a 15 minute intravenous infusion

DRUG

GC4711 105mg

single dose given via a 15 minute intravenous infusion

Trial Locations (1)

Unknown

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
lead

Galera Therapeutics, Inc.

INDUSTRY

NCT03762031 - A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers | Biotech Hunter | Biotech Hunter